Cargando…
New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels
One of the most challenging problems in the development of new anticancer drugs is the very high attrition rate. The so-called “drug repositioning process” propose to find new therapeutic indications to already approved drugs. For this, new analytic methods are required to optimize the information p...
Autores principales: | Sadacca, Benjamin, Hamy, Anne-Sophie, Laurent, Cécile, Gestraud, Pierre, Bonsang-Kitzis, Hélène, Pinheiro, Alice, Abecassis, Judith, Neuvial, Pierre, Reyal, Fabien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680301/ https://www.ncbi.nlm.nih.gov/pubmed/29123141 http://dx.doi.org/10.1038/s41598-017-14770-6 |
Ejemplares similares
-
Author Correction: New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels
por: Sadacca, Benjamin, et al.
Publicado: (2018) -
Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing data
por: Abécassis, Judith, et al.
Publicado: (2019) -
A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways
por: Hamy, Anne-Sophie, et al.
Publicado: (2016) -
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018) -
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)